A new vaccine escape mutant of hepatitis B virus causes occult infection

References

• Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337:1733-45; PMID:9392700
   PubMed Web of Science ®Google Scholar
• Shouval D. Hepatitis B vaccines. J Hepatol 2003; 39 Suppl 1:S70-76; PMID:14708681
   PubMedGoogle Scholar
• Boccalini S, Pellegrino E, Tiscione E, Pesavento G, Bechini A, Levi M, Rapi S, Mercurio S, Mannelli F, Peruzzi M, et al. Sero-epidemiology of hepatitis b markers in the population of tuscany, central italy, 20 years after the implementation of universal vaccination. Hum Vaccin Immunother 2013; 9:636-41; PMID:23354158; http://dx.doi.org/10.4161/hv.23259
   PubMed Web of Science ®Google Scholar
• Liao XY, Zhou ZZ, Wei FB, Qin HN, Ling Y, Li RC, Li YP, Nong Y, Sun KX, Li J, et al. Seroprevalence of hepatitis b and immune response to hepatitis b vaccination in chinese college students mainly from the rural areas of western china and born before hbv vaccination integrated into expanded program of immunization. Hum Vaccin Immunother 2014; 10:224-31; PMID:24018404; http://dx.doi.org/10.4161/hv.26311
   PubMed Web of Science ®Google Scholar
• Avellon A, Echevarria JM, Weber B, Weik M, Schobel U, Willems WR, Gerlich WH. European collaborative evaluation of the Enzygnost HBsAg 6.0 assay: performance on hepatitis B virus surface antigen variants. J Med Virol 2011; 83:95-100; PMID:21108344; http://dx.doi.org/10.1002/jmv.21943
   PubMedGoogle Scholar
• Jeantet D, Chemin I, Mandrand B, Tran A, Zoulim F, Merle P, Trepo C, Kay A. Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays. J Med Virol 2004; 73:508-15; PMID:15221893; http://dx.doi.org/10.1002/jmv.20119
   PubMedGoogle Scholar
• Tian Y, Xu Y, Zhang Z, Meng Z, Qin L, Lu M, Yang D. The amino Acid residues at positions 120 to 123 are crucial for the antigenicity of hepatitis B surface antigen. J Clin Microbiol 2007; 45:2971-8; PMID:17609325; http://dx.doi.org/10.1128/JCM.00508-07
   PubMedGoogle Scholar
• Weber B, Van der Taelem-Brule N, Berger A, Simon F, Geudin M, Ritter J. Evaluation of a new automated assay for hepatitis B surface antigen (HBsAg) detection VIDAS HBsAg Ultra. J Virol Methods 2006; 135:109-17; PMID:16567005; http://dx.doi.org/10.1016/j.jviromet.2006.02.009
   PubMedGoogle Scholar
• Datta S, Chatterjee S, Veer V, Chakravarty R. Molecular biology of the hepatitis B virus for clinicians. J Clin Exp Hepatol 2012; 2:353-65; http://dx.doi.org/10.1016/j.jceh.2012.10.003
   PubMedGoogle Scholar
• Ireland JH, O'Donnell B, Basuni AA, Kean JD, Wallace LA, Lau GK, Carman WF. Reactivity of 13 in vitro expressed hepatitis B surface antigen variants in 7 commercial diagnostic assays. Hepatology 2000; 31:1176-82; PMID:10796895; http://dx.doi.org/10.1053/he.2000.6407
   PubMedGoogle Scholar
• Mühlbacher A, Weber B, Bürgisser P, Eiras A, Cabrera J, Louisirirotchanakul S, Tiller FW, Kim HS, v Helden J, Bossi V, et al. Multicenter study of a new fully automated HBsAg screening assay with enhanced sensitivity for the detection of HBV mutants. Med Microbiol Immunol 2008; 197:55-64; PMID:17899185; http://dx.doi.org/10.1007/s00430-007-0059-9
   PubMed Web of Science ®Google Scholar
• Scheiblauer H, El-Nageh M, Diaz S, Nick S, Zeichhardt H, Grunert HP, Prince A. Performance evaluation of 70 hepatitis B virus (HBV) surface antigen (HBsAg) assays from around the world by a geographically diverse panel with an array of HBV genotypes and HBsAg subtypes. Vox Sang 2010; 98:403-14; PMID:20412171; http://dx.doi.org/10.1111/j.1423-0410.2009.01272.x
   PubMed Web of Science ®Google Scholar
• Jung MC, Diepolder HM, Pape GR. T cell recognition of hepatitis B and C viral antigens. Eur J Clin Invest 1994; 24:641-50; PMID:7531642; http://dx.doi.org/10.1111/j.1365-2362.1994.tb01055.x
   PubMedGoogle Scholar
• Schirmbeck R, Dikopoulos N, Kwissa M, Leithäuser F, Lamberth K, Buus S, Melber K, Reimann J. Breaking tolerance in hepatitis B surface antigen (HBsAg) transgenic mice by vaccination with cross-reactive, natural HBsAg variants. Eur J Immunol 2003; 33:3342-52; PMID:14635042; http://dx.doi.org/10.1002/eji.200324403
   PubMed Web of Science ®Google Scholar
• Bertoletti A, Costanzo A, Chisari FV, Levrero M, Artini M, Sette A, Penna A, Giuberti T, Fiaccadori F, Ferrari C. Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med 1994; 180:933-43; PMID:7520476; http://dx.doi.org/10.1084/jem.180.3.933
   PubMed Web of Science ®Google Scholar
• Khedive A, Norouzi M, Ramezani F, Karimzadeh H, Alavian SM, Malekzadeh R, Montazeri G, Nejatizadeh A, Ziaee M, Abedi F, et al. Hepatitis B virus surface protein mutations clustered mainly in CTL immune epitopes in chronic carriers: results of an Iranian nationwide study. J Viral Hepat 2013; 20:494-501; PMID:23730843; http://dx.doi.org/10.1111/jvh.12045
   PubMed Web of Science ®Google Scholar
• Bertoletti A, Sette A, Chisari FV, Penna A, Levrero M, De Carli M, Fiaccadori F, Ferrari C. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 1994; 369:407-10; PMID:8196768; http://dx.doi.org/10.1038/369407a0
   PubMed Web of Science ®Google Scholar
• Franzese O, Kennedy PT, Gehring AJ, Gotto J, Williams R, Maini MK, Bertoletti A. Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J Virol 2005; 79:3322-8; PMID:15731226; http://dx.doi.org/10.1128/JVI.79.6.3322-3328.2005
   PubMed Web of Science ®Google Scholar
• Zuckerman AJ. Effect of hepatitis B virus mutants on efficacy of vaccination. Lancet 2000; 355:1382-4; PMID:10791517
   PubMed Web of Science ®Google Scholar
• Barnaba V, Franco A, Paroli M, Benvenuto R, De Petrillo G, Burgio VL, Santilio I, Balsano C, Bonavita MS, Cappelli G, et al. Selective expansion of cytotoxic T lymphocytes with a CD4+CD56+ surface phenotype and a T helper type 1 profile of cytokine secretion in the liver of patients chronically infected with Hepatitis B virus. J Immunol 1994; 152:3074-87; PMID:7511637
   PubMed Web of Science ®Google Scholar
• Shahmoradi S, Yahyapour Y, Mahmoodi M, Alavian SM, Fazeli Z, Jazayeri SM. High prevalence of occult hepatitis B virus infection in children born to HBsAg-positive mothers despite prophylaxis with hepatitis B vaccination and HBIG. J Hepatol 2012;57:515-21; PMID:22617152; http://dx.doi.org/10.1016/j.jhep.2012.04.021
   PubMed Web of Science ®Google Scholar
• Ducos J, Bianchi-Mondain AM, Pageaux G, Conge AM, Poncet R, Vendrell JP, Segondy M, Serre A. Hepatitis B virus (HBV)-specific in vitro antibody production by peripheral blood mononuclear cells (PBMC) after vaccination by recombinant hepatitis B surface antigen (rHBsAg). Clin Exp Immunol 1996;103:15-8; PMID:8565275; http://dx.doi.org/10.1046/j.1365-2249.1996.928621.x
   PubMedGoogle Scholar
• Mancini-Bourgine M, Fontaine H, Brechot C, Pol S, Michel ML. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine 2006;24:4482-9; PMID:16310901; http://dx.doi.org/10.1016/j.vaccine.2005.08.013
   PubMed Web of Science ®Google Scholar
• Cha CH, Sohn YH, Ko SY, Oh HB. Subgenotype and serotype analysis of hepatitis b virus in korean chronic hepatitis b patients under treatment. Kor J Lab Med 2009; 29:53-8; PMID:19262079
   PubMed Web of Science ®Google Scholar